1.Fletcher C.D.M. et al. WHO Classification of Tumors: Pathology and Genetics of Tumors of Soft Tissue and Bone. Lyon: IARC Press. 2002.2.Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Вестник РОНЦ им. Н.Н. Блохина. 2011, т. 22, № 3 (85), прил. 1, c. 54-92.3.Бохян Б.Ю. Возможности лекарственного лечения локализованных сарком мягких тканей. Практическая онкология. 2004, т. 5, № 4, c. 264-267.4.Алиев М.Д. Современные подходы к лечению сарком мягких тканей. Практическая онкология. 2004, т. 5, № 4, с. 250-255.5.Gortzak E., Azzarelli A., Buesa J. et al. A randomized phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Europ. J. Cacer. 2001, v. 37, p. 1096-1103.6.Lucas D.R., Kshirsagar M.P., Biermann J.S. et al. Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation. Oncologist. 2008, v. 13, No. 4, p. 451-458.7.Eilber F.C., Rosen G., Eckardt J. et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J. Clin. Oncol. 2001, v. 19, No. 13, p. 3203-3209.8.Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009, v. 45, p. 228-247.9.Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to pErCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009, v. 50 (Suppl. 1), p. 122S-150S.10.Choi H., Charnsangavej C., de Castro Faria S. et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinibmesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR. 2004, v. 183, p. 1619-1628.11.Choi H. Response evaluation of gastrointestinal stromal tumors. The Oncologist. 2008, v. 13, suppl. 2, p. 4-7.12.Stacchiotti S., Collini P., Messina A. et al. High-grade soft-tissue sarcomas: tumor response assessment - pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology. 2009, v. 251, p. 447-456.13.Carrasco C.H., Charnsangavej C., Raymond A.K. at al. Osteosarcoma: angiographic assessment of response to preoperative chemotherapy. Radiology. 1989, v. 170, p. 839-842.14.Olieman A.F., van Ginkel R.J., Hoekstra H.J. et al. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann. Surg. Oncol. 1997, v. 4, No. 1, p. 64-69.15.Schepper A.M. De Imaging of soft tissue tumors, third edition. 2005, p. 46-60.16.Schuetze S.M., Baker L.H., Benjamin R.S., Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. The Oncologist. 2008, v. 13 (suppl. 2), p. 32-40.17.Yamamoto T., Kurosaka M., Soejima T., Fujii M. Contrast-enhanced three-dimensional helical CT for soft tissue tumors in the extremities. Skeletal Radiol. 2001, v. 30, p. 384-387.18.Vanel D., Lacombe M.J., Couanet D. et al. Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy. Radiology. 1987, v. 164, No. 1, p. 243-245.19.Wang X., Jacobs M., Fayad L. Therapeutic Response in Musculoskeletal Soft Tissue Sarcomas: Evaluation by Magnetic Resonance Imaging. NMR Biomed. 2011, v. 24, No. 6, p. 750-763.20.Sanchez R.B., Quinn S.F., Walling A., Estrada J., Greenberg H. Musculoskeletal neoplasms after intraarterial chemotherapy: correlation of MR images with pathologic specimens. Radiology. 1990, No. 174, p. 237-240.21.Erlemann R., Sciuk J., Bosse A. et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology. 1990, No. 175, p. 791-796.22.Roberge D., Skamene T., Nahal A. et al. Radiological and pathological response following pre-operative radiotherapy for soft-tissue sarcoma. Radiother. Oncol. 2010, v 97, No. 3, p. 404-407.23.Einarsdottir H., Wejde J., Bauer H. Pre-operative radiotherapy in soft tissue tumors. Assessment of response by static postcontrast MRI compared with histopathology. Acta Radiologica. 2001, v. 42, No. 1, p. 1-4.24.Shapeero L.G., Vanel D., Verstraete K.L., Bloem J.L. Dynamic contrast-enhanced MRI for soft tissue sarcomas. Semin. Musculoskeletal Radiol. 1999, v. 3, No. 2, p. 101-113.25.Hayes C., Padhani A.R., Leach M.O. et al. Assessing changes in tumor vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed. 2002, v. 15, p. 154-163.26.Verstraete K.L., van der Woude H.J., Hogendoorn P.C.W. et al. Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: basic principles and clinical applications. J. Magn. Reson. Imaging. 1996, v. 6, p. 311-321.27.Erlemann R. Dynamic gadolinium-enhanced MR imaging to monitor tumor response to chemotherapy. Radiology. 1993, v. 186, p. 904.28.Erlemann R., Sciuk J., Wuisman P. et al. Dynamic MR tomography in diagnosis of inflammatory and tumorous spaceoccupying growths of the musculoskeletal system. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. 1992, v. 156, p. 53-59.29.Verstraete K.L., Bloem J.L. Dynamic contrast-enhanced magnetic resonance imaging. Imaging of soft tissue tumors, 3rd ed. De Schepper A.M. Springer. 2006, p. 73-92.30.Le Bihan D., Turner R., Douek P., Patronas N. Diffusion MR imaging: clinical aplications. AJR. 1992, v. 159, No. 3, p. 591-599.31.Verstraete K.L., Bloem J.L. Dynamic contrast-enhanced magnetic resonance imaging. Imaging of soft tissue tumors, 3rd ed. De Schepper A.M. Springer. 2006, p. 73-92.32.Le Bihan D., Turner R., Douek P., Patronas N. Diffusion MR imaging: clinical aplications. AJR. 1992, v. 159, No. 3, p. 591-599.33.Einarsdottir H., Karlsson M., Wejde J., Bauer H.C. Diffusion-weighted MRI of soft tissue tumors. Eur. Radiol. 2004, v. 14, No. 6, p. 336-343.34.Van der Woude H.J., Bloem J.L., Schipper J. et al. Changes in tumor perfusion induced by chemotherapy in bone sarcomas: color Doppler flow imaging compared with contrast enhanced MR imaging and three-phase bone scintigraphy. Radiology. 1994, v. 191, p. 421-431.35.Van der Woude H.J., Vanderschueren G. Ultrasound in musculoskeletal tumors with emphasis on its role in tumor follow-up. Radiol. Clin. North Am. 1999, v. 37, p. 753-766.36.Bramer J.A., Gubler F.M., Maas M. et al. Colour Doppler ultrasound predicts chemotherapy response, but not survival in paediatric osteosarcoma. Pediatr. Radiol. 2004, v. 34, No. 8, p. 614-619.37.Hicks R.J. Functional imaging techniques for evaluation ofsarcomas. Cancer Imaging. 2005, v. 5, p. 58-65.38.Estes D.N., Magill H.L., Thompson E.I. et al. Primary Ewing sarcoma: follow-up with Ga-67 scintigraphy. Radiology. 1990, v. 177, No. 2, p. 449-453.39.Menendez L.R., Fideler B.M., Mirra J. Thallium-201 scanning for the evaluation of osteosarcoma and soft-tissue sarcoma. A study of the evaluation and predictability of the histological response to chemotherapy. J. Bone Joint Surg. Am. 1993, v. 75, No. 12, p. 1880-1881.40.Moustafa H., Riad R., Omar W. et al. 99mTc-MIBI in the assessment of response to chemotherapy and detection of recurrences in bone soft tissue tumors of the extremities. QJ. Nucl. Med. 2003, v. 47, p. 51-57.41.Nagaraj N., Ashok G., Waxman A. et al. Clinical usefulness of serial 99mTc sestamibiscintigraphy in evaluating tumor response to preop chemotherapy in patients with bone and soft tissue sarcomas. J. Nucl. Med. 1995, v. 36, No. 5, p. 129P (Abstract).42.Del Vecchio S., Ciarmiello A., Potena M.I. et al. In vivo detection of multidrug-resistant (MDR1) phenotype by 99m-Tc sestamibi scan in untreated breast cancer patients. Eur. J. Nucl. Med. 1997, v. 37, p. 286-289.43.Schomacker K., Schicha H. Use of myocardial imaging agents for tumor diagnosis a success story? Eur. J. Nucl. Med. 2000, v. 27, p. 1845-1865.44.Ramanna L., Waxman A., Binney G. et al. Thallium-201 scinigraphy in bone sarcoma: comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response. J. Nucl. Med. 1990, v. 31, p. 567-572.45.Jones D.N., McCowage G.B., Sostman H.D. et al. Monitoring of neoadjuvant therapy resрonse of soft-tissue and musculoskeletal sarcoma using uorine-18-FDG PET J. Nucl. Med. 1996, v. 37, No. 9, p. 1438-1444.46.Schuetze S.M., Rubin B.P., Vernon C. et al. Use of positron emission tomography in localized soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005, v. 103, p. 339-348.47.Evilevitch V., Weber W.A., Tap W.D. et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin. Cancer Res. 2008, v. 14, No. 3, p. 715-720.48.Yanagawa T., Watanabe H., Inoue T. et al. Carbon-11 choline positron emission tomography in musculoskeletal tumors: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography. J. Comput. Tomogr. 2003, v. 27, No. 2, p. 175-182.49.Iagaru A., Masamed R., Chawla S.P., Menendez L.R., Fedenko A., Conti P.S. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas. Clin. Nucl. Med. 2008, v. 33, No. 1, p. 8-13.